Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyMutual of Omaha Dry Eye Testing Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentMutual of OmahaPolicy AHS - G2138 - Evaluation of Dry Eyes

    Evaluation of Dry Eyes

    Customize your policy alerts

    Sign up for mutualofomaha Policy AHS - G2138 - Evaluation of Dry Eyes alerts

    Get alerted when Policy AHS - G2138 - Evaluation of Dry Eyes changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage for laboratory and point-of-care testing used to evaluate, assess severity of, or monitor dry eye disease. Tear osmolarity testing is covered in specified clinical situations, while MMP-9, lactoferrin, IgE, and other testing not specifically addressed do not meet coverage criteria.

    Policy Summary
    PayerMutual of Omaha
    PolicyEvaluation of Dry Eyes
    Policy CodePolicy N/A
    Change TypeReviewedno material coverage change
    Effective Date11/01/2026
    Next Review DateN/A
    Key ActionDo not order MMP-9, lactoferrin, or IgE testing for suspected dry eye disease because it does not meet coverage criteria.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was reviewed and updated, including updates to the background, guidelines and recommendations, and scientific references.

    Coverage criterion CC1 was edited for clarity and consistency.

    3Covered indications for tear osmolarity testing
    270-308 mOsm/LSuggested normal tear osmolarity range
    ≥308 mOsm/LTear-film hyperosmolarity threshold
    4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Procedure codes listed for dry-eye diagnostic testing
    0Coverage criteria modifications

    Coverage Criteria

    Tear Osmolarity Testing

    Testing of tear osmolarity meets coverage criteria when ANY of the following situations applies:

    ANY of the following

    • The individual is suspected of having dry eye disease.
    • Testing is performed to help determine the severity of dry eye disease.
    • Testing is performed to monitor the effectiveness of therapy.

    Not Covered Testing

    The following testing does not meet coverage criteria for individuals suspected of having dry eye disease:

    Any of the following testing categories

    • Testing for MMP-9 protein in human tears, when dry eye disease is suspected based on a comprehensive eye examination.
    • Testing for lactoferrin and/or IgE.
    • All other testing not discussed in this policy.

    Testing for MMP-9 protein in human tears does not meet coverage criteria.

    Testing for lactoferrin and/or IgE does not meet coverage criteria.

    For individuals suspected of having dry eye disease, all other testing not discussed above does not meet coverage criteria.

    Coding and Diagnostic Thresholds

    Applicable CPT/HCPCS Procedure CodesCPT
    82785Gammaglobulin (immunoglobulin); IgE.
    Applicable CPT/HCPCS Procedure CodesCPT
    83516Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method.
    Applicable CPT/HCPCS Procedure CodesCPT
    83520Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified.
    Applicable CPT/HCPCS Procedure CodesCPT
    83861Microfluidic analysis utilizing an integrated collection and analysis device, tear osmolarity
    Tear Osmolarity Thresholds
    CategoryNormal tear osmolarity
    Range270-308 mOsm/L
    UseSuggested range for normal eyes
    Tear Osmolarity Thresholds
    CategoryMild dry eye
    Range308-316 mOsm/L
    Use

    Provider Actions and Coverage Alerts

    Denial Risk

    MMP-9 tear testing is not covered

    Do not order MMP-9 protein testing in human tears for an individual suspected of having dry eye disease based on a comprehensive eye examination; it does not meet coverage criteria.

    Denial Risk

    Lactoferrin or IgE testing is not covered

    Do not order lactoferrin and/or IgE testing for an individual suspected of having dry eye disease; this testing does not meet coverage criteria.

    Denial Risk

    Other dry eye testing is not covered

    Avoid dry eye testing not otherwise discussed in this policy. Such testing does not meet coverage criteria because published scientific literature has not confirmed that it is required and beneficial for diagnosis and treatment.

    Background

    Dry eye disease is a multifactorial disorder of the ocular surface characterized by loss of tear-film homeostasis. Tear-film instability and hyperosmolarity, ocular-surface inflammation or damage, and neurosensory abnormalities may contribute to the disease. It may result from decreased tear production or increased evaporative loss and is commonly evaluated using symptoms, physical findings, and tear-film tests. Because no single definitive diagnostic test or universally accepted diagnostic gold standard exists, results should be interpreted with the clinical examination and other findings.

    Definitions

    Definitions
    ConditionDry eye disease (DED), also called dysfunctional tear syndrome
    Core definitionA multifactorial disease of the ocular surface characterized by loss of tear-film homeostasis and ocular symptoms
    Associated characteristicsTear-film instability and hyperosmolarity, ocular-surface inflammation and damage, and neurosensory abnormalities
    Definitions
    DefinitionA measurement of the concentration of dissolved solutes in a solution
    Clinical contextTear-film hyperosmolarity is a recognized and validated marker of dry eye disease
    Measurement unit

    Covered Indications for Tear Osmolarity Testing

    Suspected Dry Eye Disease

    Tear osmolarity testing meets coverage criteria when it is performed for a suspected diagnosis of dry eye disease.

    Suspected dry eye disease: The individual is suspected of having dry eye disease.

    Determination of Dry Eye Disease Severity

    Tear osmolarity testing meets coverage criteria when it is performed to determine the severity of dry eye disease.

    Severity assessment: Testing is performed to help determine the severity of dry eye disease.

    Monitoring Effectiveness of Dry Eye Disease Therapy

    Tear osmolarity testing meets coverage criteria when it is performed to monitor the effectiveness of dry eye disease therapy.

    Ordering Requirements

    Documentation Required

    Follow InflammaDry ordering requirements

    Use InflammaDry by prescription at point-of-care sites and in conjunction with other methods of clinical evaluation.

    Not Covered Services

    The following testing does not meet coverage criteria: MMP-9 protein testing in human tears for individuals suspected of having dry eye disease based on a comprehensive eye examination; lactoferrin and/or IgE testing for individuals suspected of having dry eye disease; and all other dry eye testing not discussed in this policy. Other unaddressed testing is not covered because published scientific literature has not established that it is required and beneficial for diagnosis and treatment.

    Policy Summary
    PayerMutual of Omaha
    PolicyEvaluation of Dry Eyes
    Policy CodePolicy N/A
    Change TypeReviewedno material coverage change
    Effective Date11/01/2026
    Next Review DateN/A
    Key ActionDo not order MMP-9, lactoferrin, or IgE testing for suspected dry eye disease because it does not meet coverage criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Diagnostic ThresholdsProvider Actions and Coverage AlertsBackgroundDefinitionsCovered Indications for Tear Osmolarity TestingOrdering RequirementsNot Covered Services
    Suggested range for mild dry eye
    Tear Osmolarity Thresholds
    CategoryModerate-to-severe dry eye
    Threshold>316 mOsm/L
    UseSuggested range for moderate-to-severe dry eye
    Normal TearLab Findings
    TestTearLab osmolarity
    Per-eye value<308 mOsm/L in each eye
    Intereye difference<8 mOsm/L
    MMP-9 Threshold
    TestInflammaDry
    AnalyteMMP-9 in the tear film
    Detection threshold>40 ng/mL
    Tear Break-Up Time
    TestTear break-up time
    Abnormal findingDark discontinuity in the tear film
    Diagnostic thresholdUnder 10 seconds
    Schirmer Test
    TestSchirmer test
    MeasurementAqueous tear production
    Abnormal threshold10 mm or less
    Tear Break-Up Time
    TestTear break-up time
    InterpretationConsidered abnormal
    ThresholdLess than 10 seconds
    Tear-Film Homeostasis
    FindingTear-film hyperosmolarity
    Threshold≥308 mOsm/L
    ApplicationIn either eye
    Tear-Film Homeostasis
    FindingInterocular tear osmolarity difference
    Abnormal threshold>8 mOsm/L
    InterpretationIndicates a departure from tear-film homeostasis
    OSDI Threshold
    IndexOcular Surface Disease Index (OSDI)
    Cutoff≥4
    Recommended actionPrompt a clinical examination
    MMP-9 Testing
    TestMMP-9 diagnostic testing
    Positive-test thresholdPast 40 ng/mL
    Clinical applicabilityUse may be most valid in more severe dry eye
    mOsm/L
    Definitions
    Full nameMatrix metallopeptidase-9 (MMP-9)
    TypeAn enzyme in the MMP family involved in wound healing and inflammation
    Source and associationProduced by corneal epithelial cells and associated with ocular-surface inflammation
    Definitions
    AbbreviationCLIA '88
    Full nameClinical Laboratory Improvement Amendments of 1988
    Related oversightCMS regulates laboratory-developed tests as high-complexity tests under CLIA
    Definitions
    ConditionDry eye disease
    DefinitionA multifactorial, symptomatic disease characterized by loss of homeostasis of the tear film and/or ocular surface
    Etiological factorsTear-film instability, hyperosmolarity, inflammation, damage, and neurosensory abnormalities
    Definitions
    DefinitionA test developed and validated by a laboratory
    RegulationRegulated by CMS as a high-complexity test under CLIA '88
    FDA statusNot approved or cleared by the FDA unless separately authorized; FDA clearance or approval is not currently required for clinical use
    Therapy monitoring: Testing is performed to monitor effectiveness of therapy.